Is It Too Late To Consider Regeneron (REGN) After Its 31% One‑Year Rally?

• This article examines whether Regeneron Pharmaceuticals, at around US$746 a share, is still offering value or if the easy gains are behind it, by walking through what the numbers indicate about the stock's price tag.
• The share price is roughly flat over the past month at 0.1%, but that follows a 31.4% return over the last year and a 3‑year period that shows an 8.3% decline.
• Recent coverage has focused on Regeneron as a key player in large cap biotech, with commentary around its product portfolio and position in the sector shaping how investors view both risk and opportunity. At the same time, analysts and financial media have been revisiting valuation metrics and peer comparisons, which can influence how investors respond to any new headlines.
• Simply Wall St's valuation model currently gives Regeneron a value score of 5 out of 6. The rest of this article will unpack how different valuation approaches arrive at that view and outline a more complete way to think about what the stock is worth by the end.

Find out why Regeneron Pharmaceuticals's 31.4% return over the last year is lagging behind its peers.

Approach 1: Regeneron Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts those projections back to today’s dollars to estimate what the entire business might be worth right now.

For Regeneron Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $3.94b. Analysts supply detailed forecasts for the next few years, and Simply Wall St then extends those estimates further out, arriving at a projected free cash flow of about $8.12b in 2030. These cash flows, plus later extrapolated years, are all discounted back to today using a required rate of return.

On this basis, the DCF model points to an estimated intrinsic value of about $1,979.49 per share. Compared with the current share price around $746, that indicates the stock is approximately 62.3% undervalued according to this specific set of assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Regeneron Pharmaceuticals is undervalued by 62.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Regeneron Pharmaceuticals.

Approach 2: Regeneron Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. It connects directly to what the business is already generating today, which many investors find easier to interpret than long range forecasts alone.

What counts as a "normal" or "fair" P/E depends on how the market views a company’s growth prospects and risks. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually points to a lower one.

Regeneron Pharmaceuticals currently trades on a P/E of about 17.0x. That sits close to the Biotechs industry average of around 17.5x and below the peer group average of roughly 23.3x. Simply Wall St also calculates a proprietary Fair Ratio of 25.3x, which reflects factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because this Fair Ratio blends those drivers into a single figure, it can be more tailored than a simple comparison with peers or the broad industry.

Comparing the current P/E of 17.0x with the Fair Ratio of 25.3x suggests Regeneron Pharmaceuticals appears undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Regeneron Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Regeneron Pharmaceuticals to the numbers, link that story to a forecast for revenue, earnings and margins, and then see the fair value that falls out of those assumptions, all inside the Community page where millions of investors share their views.

In practice, that means you might align with a more optimistic Regeneron view, where a fair value near US$1,030 reflects expectations for faster revenue growth and higher margins. Alternatively, you might align with a more cautious view, where a fair value around US$730 builds in lower growth and more pressure on earnings. You can then compare each fair value with the current share price to decide whether the stock looks expensive or cheap against your own thesis.

Because these Narratives update automatically when new earnings, product news or analyst estimates are added to the platform, you can see in real time how fresh information shifts the numbers behind your story without needing to rebuild a full model every time.

For Regeneron Pharmaceuticals, however, we'll make it really easy for you with previews of two leading Regeneron Pharmaceuticals Narratives:

Think of these as two clear stories built off the same set of company facts and analyst numbers, but reaching different conclusions about what feels reasonable to pay for the stock today.

🐂 Regeneron Pharmaceuticals Bull Case

Fair value in this bullish narrative: US$873.78 per share.

At a last close of US$746.46, this implies the shares trade at about 14.6% below that fair value estimate.

Revenue growth assumption used in this narrative: 9.2% a year.

• Focuses on an expanding immunology and broader pipeline, including Dupixent, oncology assets and potential new indications, as key drivers of future earnings.
• Highlights the role of R&D and advanced manufacturing as supports for margins and the company’s ability to scale new therapies efficiently.
• Flags concentration in EYLEA, regulatory timing, pricing pressure and high R&D spend as risks that could challenge the more optimistic outlook if they do not break in the company’s favor.

🐻 Regeneron Pharmaceuticals Bear Case

Fair value in this more cautious narrative: US$730.00 per share.

At a last close of US$746.46, this implies the shares trade at about 2.3% above that fair value estimate.

Revenue growth assumption used in this narrative: 5.5% a year.

• Emphasizes reliance on a handful of core products, exposure to biosimilar competition and global pricing pressure as constraints on revenue and margin resilience.
• Assumes slower top line growth and lower profitability, with higher R&D and demographic trends weighing on long term earnings power.
• Balances those concerns against a broad late stage pipeline, solid cash position and ongoing portfolio transitions, arguing that these factors help keep the stock closer to fairly valued in this setup.

If you want to see how these narratives are built in full, including the detailed earnings paths and risk checks that sit behind each one, To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Regeneron Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com